Consolidated figures · ₹ crore
| ₹ Cr | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1,680 | 1,677 | 1,759 | 1,732 | 1,752 | 1,822 | 1,929 | 1,901 | 1,966 | 2,123 | 2,290 | 2,229 | |
| COGS | 557 | 536 | 527 | 562 | 555 | 574 | 626 | 618 | 597 | 716 | 713 | 749 |
| Gross profit | 1,123 | 1,141 | 1,231 | 1,170 | 1,198 | 1,247 | 1,303 | 1,283 | 1,370 | 1,406 | 1,577 | 1,481 |
| 872 | 910 | 956 | 919 | 908 | 960 | 957 | 993 | 1,029 | 1,117 | 1,237 | 1,233 | |
| 251 | 231 | 275 | 252 | 289 | 287 | 345 | 290 | 341 | 289 | 339 | 248 | |
| OPM % | 14.9% | 13.8% | 15.6% | 14.5% | 16.5% | 15.8% | 17.9% | 15.2% | 17.4% | 13.6% | 14.8% | 11.1% |
| Depreciation | 97 | 95 | 101 | 91 | 91 | 91 | 95 | 98 | 105 | 121 | 117 | 127 |
| Interest | 66 | 71 | 73 | 71 | 61 | 56 | 53 | 49 | 50 | 56 | 57 | 54 |
| 10 | 36 | -155 | 410 | 8 | -10 | 9 | 12 | 4 | -19 | 10 | 20 | |
| Profit before tax | 98 | 101 | -54 | 500 | 144 | 131 | 206 | 154 | 190 | 93 | 176 | 86 |
| Tax | 36 | 35 | 8 | 18 | 42 | 30 | 55 | 52 | 70 | 38 | 57 | 30 |
| Tax % | 36.6% | 34.3% | 15.1% | 3.6% | 29% | 22.8% | 26.6% | 33.6% | 37% | 40.3% | 32.2% | 34.7% |
| 62 | 66 | -62 | 482 | 103 | 101 | 151 | 103 | 120 | 56 | 119 | 56 | |
| PAT margin % | 3.7% | 4% | -3.5% | 27.8% | 5.9% | 5.5% | 7.8% | 5.4% | 6.1% | 2.6% | 5.2% | 2.5% |
| EPS (₹) | 3.9 | 4.2 | -3.7 | 30.4 | 6.5 | 6.4 | 9.7 | 6.5 | 7.6 | 3.5 | 7.6 | 3.6 |
| Results filing | — | — | — | — | — | — | — | Results filing for Jun 2025 | Results filing for Sep 2025 | Results filing for Dec 2025 | Results filing for Mar 2026 | Results filing for Jun 2026 |
| vs same quarter last year | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % | +5.1% | +8% | +4.8% | +9.1% | +4.3% | +8.6% | +9.7% | +9.8% |
As reported in NSE results XBRL. Segment result is before tax and finance costs.
Latest reported period · 30 Jun 2026 · ₹ crore
| Segment | Revenue | Result | Assets | Liabilities | Capital employed |
|---|---|---|---|---|---|
| Radiopharma | 1,022.1 | 78 | 3,857.2 | 1,258.7 | 2,598.5 |
| Contract Development and Manufacturing Organisation - Sterile Injectables | 519.8 | 7.3 | 6,355.1 | 2,766.2 | 3,588.9 |
| +12.2% |
| +16.5% |
| +18.7% |
| +17.3% |
| PAT YoY % | +1,162.2% | — | — | +7,930% | +65.1% | +51.7% | — | -78.7% | +17% | -44.6% | -21.2% | -45% |
| Contract Research, Development and Manufacturing Organisation | 325.8 | 35.6 | 1,766.9 | 455.7 | 1,311.2 |
| Allergy Immunotherapy | 214.4 | 63.5 | 624.1 | 104.8 | 519.3 |
| Generics | 173.4 | -10.1 | 1,178.7 | 241.5 | 937.2 |
| Unallocable Corporate | 14.2 | 0 | 0 | 0 | — |
| Proprietary Novel drugs | 0 | -7.6 | 338.4 | 13.9 | 324.5 |
₹ crore by quarter